Cormorant Asset Management as of June 30, 2019
Portfolio Holdings for Cormorant Asset Management
Cormorant Asset Management holds 68 positions in its portfolio as reported in the June 2019 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
---|---|---|---|---|---|
Mirati Therapeutics | 7.7 | $134M | 1.3M | 103.00 | |
Turning Point Therapeutics I | 7.3 | $127M | 3.1M | 40.70 | |
Biohaven Pharmaceutical Holding | 5.3 | $92M | 2.1M | 43.79 | |
Spdr Series Trust S&p Biotech Put Option (XBI) | 4.5 | $79M | 900k | 87.71 | |
Reata Pharmaceuticals Cl A | 4.4 | $76M | 806k | 94.35 | |
Apellis Pharmaceuticals (APLS) | 4.3 | $75M | 3.0M | 25.34 | |
Bridgebio Pharma (BBIO) | 4.3 | $75M | 2.8M | 26.97 | |
Ascendis Pharma A S Sponsored Adr (ASND) | 4.3 | $75M | 650k | 115.15 | |
Uniqure Nv SHS (QURE) | 3.1 | $55M | 700k | 78.15 | |
Stoke Therapeutics (STOK) | 3.1 | $55M | 1.9M | 29.17 | |
Axonics Modulation Technolog (AXNX) | 2.9 | $51M | 1.3M | 40.97 | |
Tricida | 2.7 | $47M | 1.2M | 39.46 | |
Principia Biopharma | 2.6 | $45M | 1.4M | 33.19 | |
Anaptysbio Inc Common (ANAB) | 2.3 | $40M | 700k | 56.42 | |
Quotient SHS | 2.0 | $36M | 3.8M | 9.35 | |
Sarepta Therapeutics (SRPT) | 2.0 | $34M | 225k | 151.95 | |
Blueprint Medicines (BPMC) | 1.9 | $33M | 350k | 94.33 | |
Crispr Therapeutics Namen Akt (CRSP) | 1.9 | $33M | 700k | 47.10 | |
Rocket Pharmaceuticals (RCKT) | 1.8 | $31M | 2.1M | 15.00 | |
Allakos (ALLK) | 1.6 | $28M | 650k | 43.33 | |
Kura Oncology (KURA) | 1.6 | $28M | 1.4M | 19.69 | |
Myokardia | 1.4 | $25M | 500k | 50.14 | |
Y Mabs Therapeutics (YMAB) | 1.3 | $23M | 1.0M | 22.87 | |
Galapagos Nv Spon Adr (GLPG) | 1.3 | $23M | 175k | 129.01 | |
Chemocentryx | 1.3 | $22M | 2.4M | 9.30 | |
Argenx Se Sponsored Adr (ARGX) | 1.2 | $21M | 150k | 141.58 | |
Array BioPharma | 1.2 | $21M | 450k | 46.33 | |
Twist Bioscience Corp (TWST) | 1.2 | $21M | 706k | 29.01 | |
Sage Therapeutics (SAGE) | 1.1 | $18M | 100k | 183.09 | |
Eidos Therapeutics | 1.0 | $17M | 552k | 31.08 | |
Constellation Pharmceticls I | 0.9 | $16M | 1.3M | 12.28 | |
Vertex Pharmaceuticals Incorporated (VRTX) | 0.9 | $16M | 85k | 183.38 | |
Nextcure (NXTC) | 0.9 | $15M | 1.0M | 14.98 | |
Akero Therapeutics (AKRO) | 0.8 | $15M | 768k | 19.15 | |
Gossamer Bio (GOSS) | 0.8 | $14M | 643k | 22.18 | |
Nektar Therapeutics (NKTR) | 0.8 | $14M | 400k | 35.58 | |
X4 Pharmaceuticals (XFOR) | 0.8 | $13M | 890k | 15.00 | |
Eiger Biopharmaceuticals | 0.7 | $12M | 1.2M | 10.60 | |
Inspire Med Sys (INSP) | 0.7 | $12M | 200k | 60.65 | |
Phasebio Pharmaceuticals | 0.7 | $12M | 906k | 13.12 | |
Arena Pharmaceuticals Com New | 0.7 | $12M | 200k | 58.63 | |
Health Sciences Acqustn Corp Unit 04/01/2024 | 0.7 | $12M | 1.1M | 10.60 | |
Autolus Therapeutics Spon Ads (AUTL) | 0.6 | $11M | 700k | 16.10 | |
Ra Pharmaceuticals | 0.6 | $11M | 350k | 30.07 | |
Zai Lab Adr (ZLAB) | 0.6 | $11M | 300k | 34.87 | |
Orchard Therapeutics Ads | 0.6 | $10M | 730k | 13.99 | |
Amarin Corp Spons Adr New (AMRN) | 0.6 | $9.7M | 500k | 19.39 | |
Rubius Therapeutics | 0.5 | $9.4M | 600k | 15.73 | |
Harpoon Therapeutics | 0.5 | $8.4M | 650k | 13.00 | |
Atreca Cl A Com (BCEL) | 0.5 | $8.4M | 445k | 18.84 | |
Atara Biotherapeutics | 0.5 | $8.0M | 400k | 20.11 | |
Kezar Life Sciences (KZR) | 0.4 | $7.5M | 968k | 7.71 | |
Genfit S A Ads (GNFT) | 0.4 | $6.3M | 320k | 19.75 | |
Precision Biosciences Ord | 0.4 | $6.2M | 468k | 13.25 | |
Homology Medicines | 0.3 | $5.9M | 300k | 19.57 | |
Inflarx Nv (IFRX) | 0.3 | $4.7M | 1.5M | 3.16 | |
Avrobio Ord (AVRO) | 0.3 | $4.5M | 275k | 16.26 | |
Neurocrine Biosciences (NBIX) | 0.2 | $4.2M | 50k | 84.44 | |
Minerva Neurosciences | 0.2 | $3.4M | 608k | 5.63 | |
Audentes Therapeutics | 0.2 | $2.8M | 75k | 37.87 | |
Iterum Therapeutics SHS | 0.2 | $2.7M | 396k | 6.88 | |
Scholar Rock Hldg Corp (SRRK) | 0.1 | $2.4M | 150k | 15.86 | |
Abeona Therapeutics | 0.1 | $1.7M | 350k | 4.78 | |
Acceleron Pharma | 0.1 | $1.6M | 40k | 41.08 | |
Aclaris Therapeutics (ACRS) | 0.0 | $548k | 250k | 2.19 | |
Outlook Therapeutics *w Exp 02/18/202 | 0.0 | $46k | 417k | 0.11 | |
Outlook Therapeutics Com New | 0.0 | $32k | 16k | 2.03 | |
Cellectar Biosciences *w Exp 08/20/201 | 0.0 | $3.0k | 53k | 0.06 |